Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.

This ends a drawn out legal battle brought by Genevant and Arbutus against Moderna under a week before the jury trial was set to begin.

CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing ...

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for Moderna’s vaccine in the U.S.

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that, in response to a prior Refusal-to-File (RTF) letter, the Company engaged with the U.S ...

The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center ...